, 50 consecutive patients with high-risk neuroblastoma were assigned to receive tandem HDCT (high-dose chemotherapy)/auto-SCT after nine cycles of induction chemotherapy. CEC (carboplatin þ etoposide þ cyclophosphamide) regimen and TM (thiotepa þ melphalan)-TBI regimen (or TM regimen for stage 3 patients) were the first and second HDCT regimens. Local radiotherapy, differentiation therapy with 13-cis-retinoid acid and immunotherapy with interleukin-2 were given after tandem HDCT/auto-SCT. Of the 50 patients, 49 underwent a first HDCT/auto-SCT and 47 underwent a second HDCT/auto-SCT. The tumor relapsed or progressed in 14 patients, secondary malignancy developed in one patient and one patient died from chronic lung disease. Therefore, 34 patients remained event free with a median follow-up of 54.5 months (range, 14-94 months) from diagnosis. The probabilities of 5-year OS and EFS for all 50 patients were 77.0% (95% confidence interval (CI), 63.7-90.3) and 71.4% (95% CI, 58.7-84.1), respectively. However, all patients who remained event free for 43 years after tandem HDCT/auto-SCT experienced late adverse effects. Chemotherapeutic dose-escalation strategy using tandem HDCT/auto-SCT was very encouraging for survival. However, further studies incorporating newer treatment modalities are needed to reduce late adverse effects without jeopardizing the survival rate.
INTRODUCTION
Although high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) have improved the prognosis of patients with high-risk neuroblastoma, the outcome is still unsatisfactory. [1] [2] [3] [4] The main cause of failure after HDCT/auto-SCT is relapse or tumor progression rather than treatment-related mortality (TRM). In this context, some investigators have explored the efficacy of double or triple tandem HDCT/auto-SCT to further improve the outcome of high-risk neuroblastoma patients. Results suggest that further dose escalation might result in further improvements in the EFS of these patients. [5] [6] [7] We previously reported our experience on tandem HDCT/auto-SCT in patients with high-risk neuroblastoma. 7 Our retrospective analysis suggested that the EFS was encouraging despite a high TRM rate, particularly during the second HDCT/auto-SCT. A longer induction treatment (X9 courses of chemotherapy) before HDCT/ auto-SCT was associated with a better outcome. The outcome of patients who received TBI and/or local radiotherapy (RT) was better than those who did not. However, TBI in the first HDCT/ auto-SCT and a shorter interval (o12 weeks) between the first and second HDCT/auto-SCT were associated with a higher TRM rate in the second HDCT/auto-SCT. In this context, we prospectively evaluated the feasibility and effectiveness of a new tandem HDCT/ auto-SCT strategy, reflecting our previous report, that is, 9 cycles of induction chemotherapy, TBI in the second HDCT/auto-SCT, local RT in all patients and a 12-week interval between the first and second HDCT/auto-SCT.
PATIENTS AND METHODS Patients
From January 2004 to December 2008, a total of 95 patients were newly diagnosed with neuroblastoma or were transferred to Samsung Medical Center before initiation of induction chemotherapy. Fifty of them had high-risk neuroblastoma and were assigned to receive tandem HDCT/auto-SCT after induction treatment. A diagnosis of neuroblastoma was made based on either histological examination of tumor specimens or bone marrow infiltrated with neuroblastoma cells and elevated urine catecholamine levels. Tumor extent was evaluated using computerized tomography/magnetic resonance imaging, a technetium-99 ( 99 Tc) bone scan, bilateral bone marrow aspirates and biopsy specimens and an 8 MYCN copy number was determined using quantitative reverse transcriptasepolymerase chain reaction and tumors were classified with favorable or unfavorable histology according to the International Neuroblastoma Pathology Classification. 9 Patients with MYCN-amplified tumors and patients over 1 year of age with stage 4 tumor were stratified as high risk. The Samsung Medical Center Institutional Review Board approved this study and written informed consent was obtained from the parents of each patient.
Induction therapy
Six cycles of chemotherapy were given before definitive surgery except for patients who had undergone surgical resection before the administration of induction chemotherapy. Three cycles of postoperative chemotherapy were given before HDCT/auto-SCT. The CEDC (cisplatin þ etoposide þ doxorubicin þ cyclophosphamide) and ICE (ifosfamide þ carboplatin þ etoposide) regimens were alternated ( Table 1 ). The chemotherapy dose was reduced for patients younger than 24 months of age, that is, the kg base dose for o6 months of age, 70% of dose based on body surface area for 6-11 months of age, 80% of dose for 12-17 months of age and 90% of dose for 18-23 months of age. Induction chemotherapy cycles were scheduled 28 days apart but delays were permitted to allow the absolute neutrophil count (ANC) to recover to 1.0 Â 10 9 /L and the platelet count to 100 Â 10 9 /L. PBSCs were collected during the seventh chemotherapy cycle if the bone marrow was clear after the sixth chemotherapy cycle. Otherwise, this was postponed until the recovery phase after the ninth chemotherapy cycle. The aim was to collect a minimum of 2 Â 10 6 CD34 þ cells/kg (with a goal of 45 Â 10 6 ) to rescue bone marrow after tandem HDCT with the PBSCs collected during a single leukapheresis round.
Tandem HDCT/auto-SCT After the completion of induction treatment, patients underwent tandem HDCT/auto-SCT. The CEC (carboplatin þ etoposide þ cyclophosphamide) regimen and TM (thiotepa þ melphalan)-TBI regimen (or TM regimen for stage 3 patients) were used for the first and second HDCT ( Table 1) . We allowed a 12-week interval between the first and second HDCT/auto-SCT to reduce toxicity in the second HDCT/auto-SCT. No treatment was administered between the first and second HDCT/auto-SCT. Roughly half of the PBSCs collected were infused for bone marrow rescue at each HDCT/ auto-SCT session.
Post-HDCT/auto-SCT treatment Local RT (15 Gy/1.5 Gy for complete resection of the primary tumor and 21.6-30.6 Gy/1.8 Gy for incomplete resection) was administered to all patients 6 weeks after the second HDCT/auto-SCT. Differentiation therapy with 13-cis-retinoic acid (CRA; 125 mg/m 2 /day for 14 days every 4 weeks) was usually initiated at around 9 weeks after the second HDCT/auto-SCT and was administered until 1 year after the second HDCT/auto-SCT. CRA was used at a lower dose than the standard, but for longer duration because organ functions were not fully recovered within a few months after tandem HDCT/auto-SCT in many patients. Immunotherapy with interleukin-2 (IL-2; 2 Â 10 6 U/m 2 /day, subcutaneous injection for 5 consecutive days every 4 weeks) was also initiated at around 9 weeks after the second HDCT/auto-SCT if the platelet count exceeded 50 Â 10 9 /L without transfusion. If the platelet count did not exceed 50 Â 10 9 /L, immunotherapy was postponed until recovery. The first dose of IL-2 was given on the first day of the CRA treatment cycle and was administered until 1 year after the second HDCT/auto-SCT. 7 
Response criteria
International response criteria for neuroblastoma were used to evaluate the treatment response. 8 Briefly, a complete response (CR) was defined as no identifiable tumor with normal catecholamine. A very good partial response (VGPR) was defined as a reduction of the primary tumor by 90-99% with normal catecholamine with or without any residual 99 Tc bone changes. A partial response (PR) was defined as a reduction of the primary tumor and metastatic tumor by 450%. An MR (mixed response) was defined as a reduction of any measurable lesion by 450% with a reduction of any other lesion by o50%. A progression (PD) was defined as any new lesion or increase of any measurable lesion by 425%.
Evaluation of late adverse effects
Cardiac, renal, respiratory, endocrine, dental, auditory and ophthalmologic functions were evaluated before tandem HDCT/auto-SCT and at 1, 3 and 5 years after the second HDCT/auto-SCT to detect possible late adverse effects. Neurocognitive function was evaluated at 3 years after the second HDCT/auto-SCT. Toxicity was recorded according to the common terminology criteria for adverse events (version 4.0) of the US National Cancer Institute. Neurocognitive function was evaluated using the KoreanWechsler Preschool and Primary Scale of Intelligence (o6 years of age) or Korean version of Wechsler Intelligence Scale for children-III (X6 years of age).
Statistics
The survival rate with 95% confidence interval (CI) was estimated using the Kaplan-Meier method. An event was defined as relapse, progression, secondary malignancy or death. A patient who was transferred to another hospital in PR after the first HDCT/auto-SCT was censored at the time of transfer. Differences in neutrophil and platelet recovery between the first and second HDCT/auto-SCT were analyzed using a paired t-test. Differences in the frequency of adverse effects between the first and second HDCT/auto-SCT were analyzed using a w 2 test or Fisher's exact test. P-values o0.05 were considered significant. Table 2 lists patient characteristics. The median age at diagnosis was 37.5 months (range, 4-129 months) and 42 patients were over Induction treatment Surgery was done before initiation of induction chemotherapy in five patients and after six cycles of chemotherapy in 42 patients. The remaining three patients did not undergo surgery due to disappearance of the primary tumor during induction chemotherapy in two patients and tumor progression in one. Gross total resection of the primary tumor was possible in 38 patients. No significant organ toxicity other than neutropenic fever was observed in any patients except for one who experienced renal insufficiency during the postoperative period. In one patient, the tumor progressed during induction chemotherapy and the patient died of tumor progression despite salvage treatment. The remaining 49 patients proceeded to the first HDCT/auto-SCT. Of these, five received a total of 10 cycles of induction chemotherapy for scheduling HDCT/auto-SCT. Tumor status before the first HDCT/auto-SCT was CR for 24 patients, VGPR for 13, PR for 11 and MR for 1. A median of 4.7 Â 10 6 CD34 þ cells/kg (range, 1.4-38.9) was collected during the first leukapheresis round with a median of five leukapheresis events (range, [3] [4] [5] [6] [7] [8] [9] [10] [11] . One patient underwent a second leukapheresis round to collect at least 2 Â 10 6 CD34 þ cells/kg. Generally, the procedure was well tolerated and no patient developed significant toxicity except for thrombocytopenia requiring a transfusion after leukapheresis.
RESULTS

Patient characteristics
Tandem HDCT/auto-SCT Overall, 49 patients underwent the first HDCT/auto-SCT. The median age at the first HDCT/auto-SCT was 47 months (range, 15-140). Two patients could not proceed to the second HDCT/ auto-SCT because of life-threatening myocarditis during the first HDCT/auto-SCT in one patient and transfer to another hospital at the parent's request before the second HDCT/auto-SCT in the other. Thus, 47 patients underwent the second HDCT/auto-SCT as scheduled.
A median of 2.1 Â þ cell number (o2 Â 10 6 /kg) was associated with a delayed neutrophil recovery in both the first and second HDCT/auto-SCT (P ¼ 0.005 and 0.012), but not with a platelet recovery. The number of CD34 þ cells infused was not associated with the frequency of toxicities during tandem HDCT/auto-SCT. Table 3 lists grade 3/4 toxicities that developed within 1 month of each HDCT/auto-SCT. The median durations of high fever (body temperature X38.0 1C) were 4 days (range, 0-10) and 7 days (range, 2-27) for the first and second HDCT/auto-SCT (Po0.001). There were seven positive blood cultures (four in the first and three in the second HDCT/auto-SCT). The grade 3/4 toxicities that frequently developed in more than one-third of patients were vomiting, diarrhea, an elevation of the liver enzyme and hypokalemia in the first HDCT/auto-SCT and stomatitis, diarrhea and hypokalemia in the second HDCT/auto-SCT. Most patients experienced severe oropharyngeal and abdominal pain during the second HDCT/auto-SCT. Renal insufficiency developed in two 
Median (range).
Tandem HDCT/auto-SCT for high-risk neuroblastoma KW Sung et al patients during the first HDCT/auto-SCT and three during the second. Myocarditis developed in two patients during the first HDCT/auto-SCT, one of whom required extracorporeal membrane oxygenation and could not proceed to the second HDCT/auto-SCT. We observed no difference in the frequency of hepatic venoocclusive disease between the first and second HDCT/auto-SCT. No TRM occurred during tandem HDCT/auto-SCT.
Feasibility of post-HDCT/auto-SCT therapy A median of 10 cycles (range, 1-11) of CRA treatment was administered. In five patients, CRA treatment was postponed or stopped earlier than scheduled because of elevated serum creatinine. Skin eruption, particularly on the face, was a common adverse effect of CRA treatment. A median of 8 cycles (range, 0-11) of IL-2 treatment was administered. In seven patients, IL-2 was not administered because the platelet level did not reach 50 Â 10 9 /L until 1 year after the second HDCT/auto-SCT. High fever, thrombocytopenia and local inflammation were frequent adverse effects of IL-2 treatment. However, no life-threatening adverse effects related to CRA/IL-2 treatment were observed.
Patient Survival
Tumor relapse or progression was seen in 14 patients (1 during induction treatment and 13 after the second HDCT/auto-SCT). One patient died from chronic lung disease at 62 months after the second HDCT/auto-SCT. Secondary malignancy (stage 1 papillary urothelial carcinoma in bladder) developed in one patient at 61 months after the second HDCT/auto-SCT. However, this patient remained relapse-free for 26 months after complete resection of the second tumor. Therefore, 34 out of 50 patients remained event-free with a median follow-up of 54.5 months (range, 14-94) from diagnosis. The probabilities of 5-year OS and EFS for all 50 patients were 77.0% (95% CI, 63.7-90.3) and 71.4% (95% CI, 58.7-84.1), respectively. The probabilities of 7-year OS and EFS were 72.5% (95% CI, 57.3-87.7) and 63.0% (95% CI, 47.4-78. Late adverse effects Of the 23 patients who remained event-free for 43 years after the second HDCT/auto-SCT, 21 were evaluated for the presence of various late adverse effects (Table 4 ). All 21 patients experienced more than one late adverse effect, 17 more than 2, 13 more than 3 and 7 more than 4. The median number of late adverse effects per patient was 4 (range, 1-7). Dental abnormality, hearing loss, nephropathy and short stature were common late adverse effects. Two-thirds of patients who remained event free for 43 years after the second HDCT/auto-SCT had grade 1 or 2 nephropathy. In addition, 2 of the 13 patients who remained event free for o3 years after the second HDCT/auto-SCT had chronic renal failure Months from diagnosis Probability of survival (%) Figure 1 . Kaplan-Meier analysis for survival. Of the 50 patients, 34 remained event free with a median follow-up of 54.5 months (range, 14-94) from diagnosis. The probabilities of 5-year OS and EFS for all 50 patients were 77.0% (95% CI, 63.7-90.3) and 71.4% (95% CI, 58.7-84.1), respectively. The probabilities of 7-year OS and EFS were 72.5% (95% CI, 57.3-87.7) and 63.0% (95% CI, 47.4-78.6), respectively.
Tandem HDCT/auto-SCT for high-risk neuroblastoma KW Sung et al requiring hemodialysis. Seventeen (81.0%) patients had a height below the mean for age and gender. The median height at 3 years after the second HDCT/auto-SCT was À 1.25 standard deviations from the mean (range, À 5.29 to 1.62). Median values for full-scale, verbal and performance IQ (intelligence quotient) were 94 (range, 68-118), 97 (range, 62-115) and 91 (range, 70-127). Six (28.6%) patients had a full-scale IQ o90 and the remaining patients had an IQ of Z90.
DISCUSSION
Our previous reports suggested that a longer induction treatment was associated with a better outcome. Therefore, the duration of induction chemotherapy was longer in the present study than those in other studies concerning HDCT/auto-SCT for high-risk NB. [2] [3] [4] [5] [6] In addition, two different and relatively intensive regimens (CEDC and ICE) were alternated during induction treatment in order to overcome possible drug resistance and to reduce drug toxicities. As a result, the response rate to induction was better in the present study than in other cooperative protocols. We believe that a longer induction treatment with two different regimens contributed to a better response in the present study.
Toxicities during induction treatment were acceptable. However, most patients experienced significant acute toxicities during tandem HDCT/auto-SCT. Severe mucositis related to TBI and/or thiotepa during the second HDCT/auto-SCT was the most difficult problem for patients during tandem HDCT/auto-SCT. The second HDCT/auto-SCT had longer high fever duration than the first HDCT/auto-SCT, even though no difference was seen in neutrophil recovery. This might be related to the more severe mucosal damage in the second HDCT/auto-SCT. In spite of substantial potentially life-threatening toxicity such as myocarditis, renal insufficiency and hepatic veno-occlusive disease during tandem HDCT/auto-SCT, no TRM occurred. Considering the high TRM rate in our previous report, particularly during the second HDCT/auto-SCT, this result is very encouraging. We believe that the changes in this study (TBI in the second but not first HDCT/auto-SCT and sufficient rest before the second HDCT/auto-SCT) might contribute to the absence of TRM in the present study.
The efficacy of tandem HDCT/auto-SCT over single HDCT/auto-SCT cannot be answered without a randomized trial. However, a few single arm trials of tandem HDCT/auto-SCT reported improved survival rates. Survival rates in the present study were also very encouraging. The probabilities for 5-year OS and EFS were over 70%. To our knowledge, these are the highest survival rates ever reported for high-risk neuroblastoma patients. We believe that all components of this protocol employing intensive treatment strategy (long and relatively intensive induction treatment, tandem HDCT/auto-SCT, inclusion of TBI in HDCT/auto-SCT for stage 4 patients, local RT for all patients and immunotherapy with IL-2) collectively contributed to the encouraging survival rates. However, tumor relapse or progression still occurred in 13 of 47 patients who completed tandem HDCT/auto-SCT. This suggests that further studies with new modalities of treatment are needed to improve the survival rates of high-risk patients. Incorporation of high-dose 131 I-MIBG treatment into HDCT/auto-SCT might be an option although it also results in late effects. [10] [11] [12] [13] [14] [15] Matthay et al.
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showed that incorporation of high-dose 131 I-MIBG treatment into HDCT/auto-SCT was feasible and effective in patients with refractory neuroblastoma. However, no studies to date have incorporated high-dose 131 I-MIBG treatment into tandem HDCT/ auto-SCT for treating newly diagnosed high-risk patients. Therefore, further studies are needed to evaluate whether incorporation of high-dose 131 I-MIBG treatment into tandem HDCT/auto-SCT is feasible and effective. Anti-GD2 treatment might also be an option to further improve the outcome after tandem HDCT/auto-SCT. [16] [17] [18] [19] [20] Recently, Yu et al. 20 showed that anti-GD2 treatment plus CRA treatment after HDCT/auto-SCT was superior to CRA treatment alone for EFS and OS. Although no studies to date have evaluated the feasibility and efficacy of anti-GD2 treatment after tandem HDCT/auto-SCT, we believe that this immunotherapy with might further improve outcomes.
Although there are some controversies regarding the efficacy of TBI, results from our previous and present studies suggest that a regimen with TBI might be better than a regimen without it in terms of the survival of patients with high-risk neuroblastoma. The survival rate in the study by George et al., which included TBI in the second HDCT/auto-SCT was also encouraging. However, a regimen with TBI inevitably results in more significant acute and late adverse effects than a regimen without. Indeed, all longterm survivors in this study had late adverse effects and still needed long-term follow-up for observation of additional late adverse effects, although they demonstrated acceptable levels of cognitive and developmental function. Dental abnormality, hearing loss, nephropathy and short stature were the most prevalent late adverse effects. While only a third of patients had a growth hormone deficiency at 3 years after the second HDCT/auto-SCT, 480% had a height less than the normal average. This suggests that the growth of survivors is influenced by not only the status of growth hormone but also by other contributing factors such as TBI in the protocol used here. Although secondary tumor developed in only one patient so far, the number of secondary tumors might increase during longer follow-up. These late adverse effects are similar to those in studies employing TBIincorporated HDCT/auto-SCT. 21, 22 These findings suggested that further studies employing new treatment modalities are needed to reduce late adverse effects without jeopardizing the survival rate. Again, incorporation of high-dose 131 I-MIBG treatment, instead of TBI, into tandem HDCT/auto-SCT and anti-GD2 treatment after tandem HDCT/auto-SCT seem to be possible options.
In summary, encouraging survival rates in the present study are limited by small number of cases. Nonetheless, the findings in the present study suggest that intensive treatment strategy employing long and intensive induction treatment, tandem HDCT/auto-SCT, incorporation of TBI, local RT and immunotherapy with IL-2 might improve the survival of high-risk neuroblastoma patients, with acceptable short-term toxicities. However, we found that late adverse effects, particularly from TBI, were unavoidable in all longterm survivors. Therefore, further studies incorporating newer treatment modalities instead of TBI are needed to reduce late adverse effects without jeopardizing the survival rate. Tandem HDCT/auto-SCT for high-risk neuroblastoma KW Sung et al
